Skip to main content
. 2024 Jun 17;12(7):941–950. doi: 10.1002/ueg2.12609

TABLE 3.

Adverse events in each therapy group.

Culture‐based tailored therapy Empirical concomitant therapy p value
(n = 229) (n = 75)
Influence on daily activity <0.001
None 124 (54.1) 21 (28.0)
Mild 77 (33.6) 28 (37.3)
Moderate 28 (12.2) 26 (34.7)
Taste alteration (%) 49 (21.4) 34 (45.3) <0.001
Grade 2 10 16
Diarrhea (%) 40 (17.5) 17 (22.7) 0.317
Grade 2 12 7
Constipation (%) 3 (1.3) 6 (8.0) 0.008
Grade 2 0 3
Abdominal pain (%) 11 (4.8) 8 (10.7) 0.095
Grade 2 3 3
Nausea (%) 20 (8.7) 9 (12.0) 0.403
Grade 2 3 4
Vomiting (%) 4 (1.7) 2 (2.7) 0.639
Grade 2 1 1
Bloating (%) 5 (2.2) 4 (5.3) 0.232
Grade 2 1 0
Belching (%) 0 (0.0) 2 (2.7) 0.060
Grade 2 0 0
Acid reflux (%) 4 (1.7) 4 (5.3) 0.106
Grade 2 0 1
Chest distress (%) 3 (1.3) 3 (4.0) 0.162
Grade 2 2 2
Dizziness (%) 7 (3.1) 11 (14.7) 0.001
Grade 2 3 6
Fatigue (%) 10 (4.4) 8 (10.7) 0.086
Grade 2 3 5
Skin rash (%) 5 (2.2) 0 (0.0) 0.338
Grade 2 0 0